Nilotinib Stada 150 Mg Tvrdé Tobolky

Nilotinib, the active ingredient in Nilotinib Stada 150 Mg Tvrdé Tobolky, is a tyrosine kinase inhibitor presented as a 150 mg tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia in the chronic phase in adult patients.

GNH USA supplies Nilotinib Stada 150 Mg Tvrdé Tobolky as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑ready documentation for importers, ensuring timely delivery and compliance with local regulations.

Nilotinib is a targeted tyrosine kinase inhibitor used in the management of Philadelphia chromosome‑positive chronic myeloid leukemia. - Chronic Myeloid Leukemia (chronic phase): reduces leukemic cell proliferation and improves long‑term survival. - Chronic Myeloid Leukemia (accelerated phase): provides disease control when prior therapy is insufficient. - Philadelphia chromosome‑positive CML after prior therapy: offers an alternative oral option for patients resistant or intolerant to first‑line treatment.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools. - Rash: skin irritation or redness. - Fatigue: feeling of tiredness.

Serious or Rare Side Effects: - QT prolongation: heart rhythm disturbance that can lead to arrhythmia. - Pancreatitis: inflammation of the pancreas with abdominal pain. - Hepatic failure: severe liver enzyme elevation and dysfunction. - Severe neutropenia: markedly reduced white blood cell count increasing infection risk.

When prescribing nilotinib, clinicians should observe several safety measures to minimize risks. - ECG monitoring: perform baseline and periodic ECGs to detect QT prolongation. - Liver function tests: assess hepatic enzymes before and during therapy. - Blood count monitoring: check complete blood count regularly for neutropenia or thrombocytopenia. - Avoid concomitant QT‑prolonging drugs: reduce risk of cardiac arrhythmias. - Dose adjustment in hepatic impairment: use caution and consider lower doses in patients with liver dysfunction. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nilotinib interacts with several medicines, requiring careful management of co‑administered drugs.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nilotinib plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce nilotinib effectiveness. - QT‑prolonging agents (e.g., quinidine, amiodarone): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: can decrease nilotinib absorption; separate dosing by at least 2 hours. - CYP3A4 substrate drugs (e.g., midazolam, tacrolimus): may have altered exposure. - Warfarin: monitor INR closely as nilotinib may affect anticoagulation.